02:38 PM EDT, 08/05/2025 (MT Newswires) -- Esperion Therapeutics ( ESPR ) shares were up 10% in recent trading on Tuesday after the drugmaker reported a narrower-than-expected loss and revenue beat in Q2.

The company earlier reported a Q2 net loss of $0.02 per diluted share, narrowing from a loss of $0.33 a year earlier.

Analysts polled by FactSet expected a loss of $0.15.

Revenue for the quarter ended June 30 rose to $82.4 million from $73.8 million a year earlier.

Analysts surveyed by FactSet expected $63 million.

Price: 1.64, Change: +0.15, Percent Change: +10.07